Poster
148
(#148) Real-World Experiences Using TV-46000 in Adults With Schizophrenia: A Qualitative Study of Healthcare Professionals
Psych Congress 2025
Abstract: Background: TV-46000 is a subcutaneous long-acting injectable antipsychotic (LAI) approved by the United States (US) Food and Drug Administration to treat adult patients with schizophrenia. This qualitative study assessed the real-world experiences with TV-46000 by healthcare professionals (HCPs) in the US.
Methods: Eligible HCPs completed a 60-minute, semi-structured, in-depth, virtual interview (June 2024-January 2025). Interview transcripts were coded, and content and thematic analyses of interview data were performed.
Results: 56 HCPs (20 physicians, 23 nurse practitioners/physician assistants [NP/PAs], 13 registered nurses [RNs]) completed the interview. Across HCP types, attributes of TV-46000 most reported as slightly/significantly better when compared with other LAIs included lack of required loading dose (89%) and subcutaneous administration (85%). When asked about their view of TV-46000 therapeutic plasma concentration compared with other LAIs, TV-46000 was more often reported as slightly/significantly better by NP/PAs (87%) and physicians (79%) than by RNs (69%). NP/PAs and RNs were more positive about TV-46000 injection volume than physicians (slightly/significantly better: 82%, 85%, and 61%, respectively). When asked to rate satisfaction with TV-46000 compared with other LAIs (scale: 1 [not at all] to 7 [very]), the average rating was 6. Most common areas of satisfaction were familiarity with TV-46000 (87%) and subcutaneous injection (67%) for physicians and effectiveness (42%), no loading dose (26%), and tolerability (26%) for NP/PAs.
Conclusions: HCPs generally reported high levels of satisfaction with TV-46000 use in the clinical setting. Across HCP types, a subcutaneous injection and no required loading dose were key product attributes of TV-46000.
Short Description: This study assessed real-world experiences with TV-46000, a long-acting injectable antipsychotic (LAI) used to treat adults with schizophrenia. Physicians (n=20), nurse practitioners/physician assistants (NP/PAs; n=23), and registered nurses (n=13) completed a 60-minute, semi-structured interview. Most HCPs reported the no required loading dose and subcutaneous administration as attributes of TV-46000 that are significantly better than other LAIs. Physicians and NP/PAs rated high satisfaction with TV-46000 (average rating of 6 on a scale from 1-7).
Name of Sponsoring Organization(s): Teva Branded Pharmaceutical Products R&D LLC
Methods: Eligible HCPs completed a 60-minute, semi-structured, in-depth, virtual interview (June 2024-January 2025). Interview transcripts were coded, and content and thematic analyses of interview data were performed.
Results: 56 HCPs (20 physicians, 23 nurse practitioners/physician assistants [NP/PAs], 13 registered nurses [RNs]) completed the interview. Across HCP types, attributes of TV-46000 most reported as slightly/significantly better when compared with other LAIs included lack of required loading dose (89%) and subcutaneous administration (85%). When asked about their view of TV-46000 therapeutic plasma concentration compared with other LAIs, TV-46000 was more often reported as slightly/significantly better by NP/PAs (87%) and physicians (79%) than by RNs (69%). NP/PAs and RNs were more positive about TV-46000 injection volume than physicians (slightly/significantly better: 82%, 85%, and 61%, respectively). When asked to rate satisfaction with TV-46000 compared with other LAIs (scale: 1 [not at all] to 7 [very]), the average rating was 6. Most common areas of satisfaction were familiarity with TV-46000 (87%) and subcutaneous injection (67%) for physicians and effectiveness (42%), no loading dose (26%), and tolerability (26%) for NP/PAs.
Conclusions: HCPs generally reported high levels of satisfaction with TV-46000 use in the clinical setting. Across HCP types, a subcutaneous injection and no required loading dose were key product attributes of TV-46000.
Short Description: This study assessed real-world experiences with TV-46000, a long-acting injectable antipsychotic (LAI) used to treat adults with schizophrenia. Physicians (n=20), nurse practitioners/physician assistants (NP/PAs; n=23), and registered nurses (n=13) completed a 60-minute, semi-structured interview. Most HCPs reported the no required loading dose and subcutaneous administration as attributes of TV-46000 that are significantly better than other LAIs. Physicians and NP/PAs rated high satisfaction with TV-46000 (average rating of 6 on a scale from 1-7).
Name of Sponsoring Organization(s): Teva Branded Pharmaceutical Products R&D LLC
